Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?

Study Overview
=================
Brief Summary
-----------------
The study will enroll patients through the Neurology Department at Naval Medical Center San Diego (NMCSD). Eligible participants will meet criteria for chronic migraine, but will not be excluded based on the presence of significant comorbidities. Participants with comorbidities and medication regimens commonly exhibited within real-world DOD medical settings will not be excluded, such as pain disorders, psychiatric illness, medication overuse, and those who have used prophylactic medication during the baseline period. This will comprise Group A. A carefully screened group will comprise Group B and meet exclusion criteria designed to approximate that of the PREEMPT2 trial. Within each group, half of the patients (155U Arm) will be randomly selected to receive the standard 155U over 31 fixed sites every 12 weeks while the other half (100U Arm) will receive 100U over 19 fixed sites every 12 weeks. Minimum sample size for the entire cohort is 132 participants (maximum n = 180), with a minimum of 66 participants per comparison.

Official Title
-----------------
OnabotulinumtoxinA for Chronic Headaches: Is 155 Units Superior to 100 Units?

Conditions
-----------------
Chronic Migraine, Headache

Intervention / Treatment
-----------------
* Drug: Dose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic migraine headache - Diagnostic criteria: A. Headache (tension-type-like and/or migraine-like) on 15 days per month for >3 months2 and fulfilling criteria B and C B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2 Migraine with aura C. On 8 days per month for >3 months, fulfilling any of the following 3 : criteria C and D for 1.1 Migraine without aura criteria B and C for 1.2 Migraine with aura believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative D. Not better accounted for by another ICHD-3 diagnosis. - Exclusion Criteria: Previous exposure at any time to any botulinum toxin serotype Pregnancy, breastfeeding or plans to become pregnant within 6 months Age <18 years Failure to complete at least 20 days of headache diary in the 28 day baseline period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A 100U<br> | Drug: Dose<br>* Randomized to either 100U or 155U<br>|
| Experimental: Group A 155U<br> | Drug: Dose<br>* Randomized to either 100U or 155U<br>|
| Experimental: Group B 100U<br> | Drug: Dose<br>* Randomized to either 100U or 155U<br>|
| Experimental: Group B 155<br> | Drug: Dose<br>* Randomized to either 100U or 155U<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mean change in frequency of headache days for the baseline period compared to the 28-day period ending with week 24 |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of migraine days |  | 24 weeks | 
| proportion of patients with severe (>=60) HIT-6 score |  | 24 weeks | 
| acute headache pain medication intakes |  | 24 weeks | 
| mean change in total HIT-6 |  | 24 weeks |